Project Grant R21AI203588
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $245K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Covington, LA, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Administrators Of Tulane Educational Fund (Tulane University) $138,808 on March 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to examine antiretroviral treatment adherence among pregnant and postpartum women living with HIV in South Africa. The research uses mixed methods to investigate how intimate partner violence alters adherence to Option B+ antiretroviral therapy during the perinatal...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $783,740 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop pharmacological interventions enhancing chimeric antigen receptor (CAR) cell-based immunotherapy for HIV-1 infection. The research investigates targeted enhancement of engineered cellular anti-HIV immunity using immune modulators. The project builds on prior studies demonstrating...
- The National Institute of Allergy and Infectious Diseases awarded $571,747 to Tulane University on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate alpha-satellite RNAs in Epstein-Barr virus lytic replication. The funded research examines how Epstein-Barr virus induces alpha-satellite RNAs—transcripts from tandem repetitive non-coding DNA sequences constituting 3–5% of the human genome—during viral lytic replication. The work explores the...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $793,623 on August 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered natural killer cells for HIV reservoir targeting. The project, titled "Engineering NK Cells for Effective HIV Reservoir Targeting (ENHANCE)," aims to create chimeric antigen receptor (CAR)-expressing natural killer cells designed to target and eliminate...
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $473,491 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop logic-gated chimeric antigen receptor (CAR) molecules targeting latently infected CD4 T cells in HIV-1-infected patients treated with antiretroviral therapy. The work addresses the inability of antiretroviral therapy to eliminate the latent HIV reservoir, which persists as...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $889,101 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enhanced natural killer cell-based strategies targeting HIV reservoirs. The recipient will develop and test tri-specific NK cell engager molecules (TRIKEs) engineered to enhance NK-mediated antibody-dependent cellular cytotoxicity (ADCC) responses against HIV-infected cells....
- The National Institute of Allergy and Infectious Diseases awarded Tulane University $382,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the role of biofilms in enterotoxigenic Escherichia coli (ETEC) pathogenesis. The research focuses on identifying novel antigens from ETEC biofilms as potential vaccine targets. ETEC causes severe diarrhea globally and contributes to child mortality and malnutrition in low- to...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded The Wistar Institute of Anatomy and Biology $506,550 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI200714). The award funds research to improve HIV-specific CAR T cell therapy by neutralizing persistent Type-I Interferon signaling. The project will identify mechanisms by which chronic interferon-beta exposure mediates HIV-specific CAR T cell dysfunction and...
- The National Institute of Allergy and Infectious Diseases awarded East Carolina University $536,695 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 1, 2026. The award funds research into the roles of fibroblastic reticular cells (FRCs) in the establishment and maintenance of HIV-1 latently infected cells containing intact proviruses in people living with HIV under antiretroviral therapy. The project examines how FRCs, a type of secondary lymphoid organ stromal...